Macquarie Group Ltd. bought a new stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 8,300 shares of the biopharmaceutical company’s stock, valued at approximately $248,000.

Several other institutional investors have also made changes to their positions in JUNO. Pacad Investment Ltd. acquired a new stake in shares of Juno Therapeutics during the second quarter valued at about $105,000. QS Investors LLC acquired a new stake in shares of Juno Therapeutics during the second quarter valued at about $135,000. Leisure Capital Management acquired a new stake in shares of Juno Therapeutics during the second quarter valued at about $255,000. Brighton Jones LLC acquired a new stake in shares of Juno Therapeutics during the second quarter valued at about $260,000. Finally, CAPROCK Group Inc. acquired a new stake in shares of Juno Therapeutics during the second quarter valued at about $299,000. Institutional investors own 67.18% of the company’s stock.

Several analysts have recently weighed in on the company. Zacks Investment Research downgraded Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Morgan Stanley raised their target price on Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday, August 7th. Maxim Group restated a “buy” rating and set a $56.00 target price on shares of Juno Therapeutics in a research note on Thursday. Vetr downgraded Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.47 target price for the company. in a research note on Monday, August 7th. Finally, Cowen and Company restated a “buy” rating and set a $49.00 target price on shares of Juno Therapeutics in a research note on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $43.20.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 33.65%. The company’s quarterly revenue was up 115.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.57) earnings per share.

ILLEGAL ACTIVITY NOTICE: “Macquarie Group Ltd. Buys Shares of 8,300 Juno Therapeutics, Inc. (JUNO)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/macquarie-group-ltd-buys-shares-of-8300-juno-therapeutics-inc-juno/1675022.html.

In other Juno Therapeutics news, insider Sunil Agarwal sold 7,285 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard Klausner sold 12,000 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $30.34, for a total transaction of $364,080.00. Following the sale, the director now directly owns 788,985 shares in the company, valued at $23,937,804.90. The disclosure for this sale can be found here. Insiders have sold 85,004 shares of company stock worth $3,551,561 over the last ninety days. Insiders own 15.26% of the company’s stock.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.